Troglitazone in combination with sulphonylurea improves glycaemic control in type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone

Diabetic Medicine

Volumn 16, Issue 2, 1999, Pages 147-153

  Buysschaert, M ^a   Bobbioni, E ^b   Starkie, M ^c   Frith, L ^c   Van Gaal, L ^d   Somers, G ^d   Reynders, P ^d   Bouillon, R ^d   Johansen, J ^d   Gilehuus, R E ^d   Furuseth, K ^d   Hansen, A N ^d   Luhdbo, C ^d   Caldeira, J ^d   Saraiva, M ^d   Correa, N ^d   Medina, L ^d   Silva, J L ^d   Robertson, L ^d   Lourens, W ^d   Bonnici, F ^d   Distiller, L ^d   Ellis, G ^d   Gomez, F ^d   Golay, A ^d   Suter, S ^d   Harrower, A D B ^d   Rayman, G ^d   Shaw, I ^d   Simpson, H C R ^d   Johnston, C ^d   White, M ^d   Hepburn, D A ^d   Beer, S F ^d   Leatherdale, B A ^d   Coppack, S ^d   Hamill, J J ^d   Fisher, B M ^d   more..

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c GLAXOSMITHKLINE   (United Kingdom)

^d NONE

Author keywords

Combination therapy; Glycaemic control; Sulphonylurea; Troglitazone; Type 2 diabetes mellitus

Indexed keywords

SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; VIRUS PNEUMONIA;

BLOOD GLUCOSE; CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032725509     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00029.x     Document Type: Article

References (15)

1. 1 Alberti KGMM, Fries FA, Jervell J, Krans HMJ. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabetic Med 1994; 11: 899-909.
2. 2 Hermann LS. Biguanides and sulfonykireas as combination therapy in NIDDM. Diabetes Care 1990; 13: 37-41.
3. 3 Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B et al. for the Troglitazone Study Group. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-709.
4. 4 Leutenegger M, Sacca L, Alderton C, Eckland D, Lettis S for the Troglitazone Study Group. Double-masked, placebo-controlled, dose-ranging study of troglitazone 10-200 mg once-daily in non-insulin-dependent diabetes mellitus. Curr Ther Res 1997; 58: 403-416.
5. 5 Schwartz S, Raskin P, Fonseca V, Graveline JF for the Troglitazone and Exogenous Insulin Study Group. Effect of troglirazone in insulintreated patients with type II diabetes mellitus. New Engl J Med 1998; 338: 861-866.
6. 6 Inzucchi SE, Maggs DG, Spollet GR, Page SL, Rife FS, Walton V et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New Engl Med 1998; 338: 867-872.
7. 7 Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterisation of new oral antidiabetic agent CS-045 Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-1558.
8. 8 Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-bd/db mice. Metabolism 1995; 44: 486-490.
9. 9 Levin K, Thye-Ronn P, Foot E, Beck-Nielsen H. Metabolic effects of troglitazone in NIDDM patients. Endocrinol Metab 1997; 4: 255-264.
10. 10 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995; 270: 12953-12956.
11. 11 Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 1997; 54: 801-808.
12. 12 Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754.
13. 13 Young MA, Eckland DJA, Eastmond R, Lettis S. Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients. Ann Med 1998; in press.
14. 14 Ghazzi M, Radke-Mitchell L, Verable T, the Troglitazone Study Group, Whitcomb R. Troglitazone improves glycemic control in patients with type 2 diabetes who are not optimally controlled on sulfonylurea. Diabetes 1997; 46 (suppl 1): P44A, 0169.
15. 15 Correa JCN, Hilsted J, Eckland D, Lettis S, Starkie M, Young M for the Troglitazone Study Group. Investigation of twice or three times daily dose regimen of troglitazone, an insulin action enhancer, in patients with non insulin dependent diabetes mellitus. Eur J Clin Res 1997; 9: 151-165.